Skip to main content

Highlights

  1. 1
    PLoS pathogens · 2024
    PMID: 38190392PMCID: PMC10898863DOISenior author7 citations
  2. 2
    Molecular cancer research : MCR · 2025
    PMID: 39883059PMCID: PMC12048277DOIeCommonsSenior author3 citations
  3. 3
    Blood cancer journal · 2026
    PMID: 42020367PMCID: PMC13392450DOISenior author1 citations

Publications

221 publications

Active

12 grants
  • MPI
    Consortium for Advancing Management and Prevention of Cancer in People with HIV - RESOURCE LAB
    National Cancer Institute · 2015–2030 · via EMMES Corporation· 7 renewals
  • MPI
    Weill Cornell Initiative for Maximizing Student Development
    National Institute of General Medical Sciences · 2024–2030Training
  • MPI
    Tri-I Stimulating Access to Research in Residency program (Tri-I StARR - NIAID)
    National Institute of Allergy and Infectious Diseases · 2023–2028
  • Co-I
    Translating molecular profiles into treatment approaches to target disparities in lymphoma
    Leukemia & Lymphoma Society · 2024–2027 · via Emory University
    LLS 7038-25
  • KP
    Targeting Unmet Needs For B-cell Lymphomas
    Leukemia & Lymphoma Society · 2022–2027
    LLS 7027-23 Project 1
  • MPI
    B cell determinants of EBV latency
    National Cancer Institute · 2022–2027· 2 renewals
  • PI
    Next-Gen Oncopathology Program
    National Cancer Institute · 2022–2027Training
  • Sub-PI
    Rapid Sample to Answer Diagnosis of Kaposi's Sarcoma Across Sub-Saharan Africa using KS-COMPLETE
    National Cancer Institute · 2022–2027 · via Cornell University - Ithaca
  • MPI
    Regulatory Crosstalk Between Human Endogenous Retroviruses, HIV, and EBV, in Lymphoma
    National Cancer Institute · 2021–2027 · via Northwell Health· 2 renewals
  • PI
    Project: Next-Gen Oncopathology Program - Charles Ng
    Memorial Sloan Kettering Cancer Center · 2025–2026
    MSKCC 260282-01
  • Co-I
    Epigenetic basis and therapeutic targeting of the unique lymphoma immunological niche
    National Cancer Institute · 2024–2026
  • PI
    (PQ 6) New Models of KSHV Oncogenesis and KS Immune Environment
    National Cancer Institute · 2020–2026· 2 renewals
Completed grants (29)
  • PI
    Role of novel onco-histone mutations in B-cell malignancies
    National Cancer Institute · 2019–2025
  • MPI
    Weill Cornell Initiative for Maximizing Student Development
    National Institute of General Medical Sciences · 2019–2025
  • KP
    Defining the evolution and tumor microenvironment interactions of classic Hodgkin lymphoma through single-cell multi-omics and genetically engineered mouse models
    Starr Cancer Consortium · 2022–2024
    I15-0016
  • MPI
    Early Stage Diagnosis of Kaposi's Sarcoma in Limited Resource Settings Using KS-Detect
    National Cancer Institute · 2016–2023 · via Cornell University - Ithaca
  • KP
    Cohesin complex regulatory proteins and chromosomal architecture in normal and malignant B-cells
    American Society of Hematology Inc · 2022–2023
    ASH 220412-01
  • MPI
    Role Of The Linker Histones H1 In Lymphomas
    American Association for Cancer Research · 2021–2023Fellowship
    AACR 212713-01
  • Co-I
    Modulation Of Viral Latency In EBV+ Lymphomas To Sensitize Tumors To Immunotherapy
    American Society of Hematology Inc · 2021–2023
    ASH 210413-01
  • KP
    Targeting Unmet Clinical Needs for B-Cell Lymphoma
    Leukemia & Lymphoma Society · 2016–2021
    7012-16 CORE A
  • KP
    Rational Translation of EZH2 Targeted Therapy in Germinal Center B-Cell Lymphoma
    National Cancer Institute · 2017–2021Career
  • PI
    Defining the Cellular Oncogenome of Kaposi Sarcoma
    National Cancer Institute · 2017–2021
  • Co-I
    Modulation of Viral Latency in EBV-Associated Lymphomas as a Mechanism to Sensitize Tumors to EBV-Directed Cellular Therapy
    Starr Cancer Consortium · 2018–2020
    I11-0043
  • PI
    Nucleoside Analogue Selectively Activated by Adenosine Kinase to Treat ADK-expressing Adenocarcinomas
    Daedalus Fund for Innovation (Weill Cornell) · 2017–2020
    DFI 180572-02
  • PI
    HHV-6 in the Lymphoma Microenvironment
    HHV-6 Foundation · 2019–2020
    HHV 200848-01
  • PI
    Service Agreement: Between WCM (PI Ethel Cesarman) and Fred Hutch (PI Warren Phipps) - Reference Grant: R21 CA206851
    Fred Hutchinson Cancer Research Center · 2017–2020Contract
    SA 183504-03
  • PI
    The 22nd International Conference on Kaposi's sarcoma-associated herpesvirus and Related Agents
    National Cancer Institute · 2019–2020
  • PI
    Elucidating the Etiologic Role of Linker Histone Mutations in Hematological Malignancy
    Starr Cancer Consortium · 2016–2019
    I9-A9-062
  • Co-I
    Targeting Metabolism in Plasma Cell Neoplasms Using a Nucleoside Analog
    Lymphoma Research Foundation · 2017–2019Fellowship
    LRF 17020210-01
  • MPI
    AIDS Clinical Trials Group (ACTG): A5178: Liver Disease Progression
    National Institute of Allergy and Infectious Diseases · 2013–2018 · via The Brigham & Women's Hospital INC· 2 renewals
  • PI
    Modeling KSHV Latency in vivo
    National Cancer Institute · 2012–2018
  • KP
    Targeting the Hsp90 Oncoproteome in Pediatric Burkitt Lymphoma
    St. Baldrick's Foundation · 2015–2018
    SBF 170821-03
  • PI
    Targeting vFLIP for the Treatment of KSHV-Associated Malignancies
    National Cancer Institute · 2011–2018
  • PI
    Immunology and Microbial Pathogenesis Research Training Program
    National Institute of Allergy and Infectious Diseases · 2010–2016Training
  • Sub-PI
    Solar-Thermal PCR Assay for the Diagnosis of Kaposi's Sarcoma in Limited Resource Settings
    National Institute of Biomedical Imaging and Bioengineering · 2013–2015 · via Cornell University - Ithaca
  • MPI
    AIDS Malignancies Clinical Trials Consortium
    National Cancer Institute · 2010–2015 · via EMMES Corporation
  • Sub-PI
    KS-Detect: A Solar-Powered and Smartphone Integrated Instrument for Point-of-Care Diagnosis of Kaposi's Sarcoma
    National Cancer Institute · 2015–2015 · via A'as, Inc.
  • MPI
    HIV-Associated Malignancy Research Pilot Projects
    National Cancer Institute · 2010–2014 · via Sloan-Kettering Institute for Cancer Research· 2 renewals
  • PI
    Survival Signals in AIDS Lymphomas
    NCI · 1995–2012 · via NIH RePORTER
  • PI
    Identifying small molecule inhibitors of KSHV vFLIP-TRAF2 interactions.
    NCI · 2006–2008 · via NIH RePORTER
  • PI
    KSHV TRANSFORMATION AND ANGIOGENESIS IN KAPOSIS SARCOMA
    NCI · 1999–2003 · via NIH RePORTER

Honors & distinctions

2 honors
  • Member · American Society for Clinical Investigation · 2001
  • Member · Association of American Physicians

Available technologies

News mentions

Show 3 more mentions
  • Weill Cornell Medicine Awarded NCI Grant For EBV-Related Lymphoma Research
    February 23, 2023

    Weill Cornell Medicine has been awarded a five-year, $4.2 million grant by the National Cancer Institute, part of the National Institutes of Health, to investigate the molecular mechanisms by which immune cells called B cells interact with Epstein-Barr virus (EBV) to cause lymphoma, particularly in people living with HIV.

  • Inaugural Mastercard Pilot Grant Program Recipients Selected
    April 6, 2022

    Five Weill Cornell Medicine faculty members have been awarded research funding from the Pilot Grant Program of the Mastercard Diversity-Mentorship Collaborative at Weill Cornell Medicine.

  • Scientists Discover a Key Genetic Driver of Lymphomas
    December 9, 2020

    Mutations in proteins called histone H1, which help package DNA in chromosomes, are a frequent cause of lymphomas, according to a study led by researchers at Weill Cornell Medicine, NewYork-Presbyterian and The Rockefeller University. The findings could lead to new approaches to treating these cancers.

External relationships

Professional Services

Fred Hutchinson Cancer Center

Proprietary Interest

Center for Technology Licensing at Cornell University

Other

Genzyme Corporation